Stock Financial Ratios, Dividends, Split History

MTRN / Materion Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price55.15
Volume72,300.00
Market Cap ($M)1,121.59
Enterprise Value ($M)1,104.02
Book Value ($M)504.33
Book Value / Share24.98
Price / Book2.22
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 20,027,000
Common Shares Outstanding 20,116,096
Weighted Average Number Of Diluted Shares Outstanding 20,415,000
Weighted Average Number Diluted Shares Outstanding Adjustment 388,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.02
Balance Sheet (mrq) ($M)
Assets777.88
Liabilities273.55
Quick Ratio1.58
Current Ratio3.48
Income Statement (mra) ($M)
Sales Revenue Goods Net1,139,447,000.00
Reimbursement Revenue63,500,000.00
Entity Wide Revenue Major Customer Threshold0.10
Revenue Value Added Sales677,697,000.00
Operating Income38.58
Net Income11.45
Earnings Per Share Basic0.57
Earnings Per Share Diluted0.56
Cash Flow Statement (mra) ($M)
Cash From Operations67.80
Cash from Investing-43.36
Cash from Financing-43.36
Identifiers and Descriptors
CUSIP576690101
Central Index Key (CIK)1104657
Related CUSIPS
576690951 576690901

Split History

Stock splits are used by Materion Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

32m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

RPM International: Limited Upside, But Enjoy The Dividends

2018-06-11 seekingalpha
RPM International sells coatings, sealants and building materials through three core segments: Industrial, Consumer and Specialty. (7-0)

Esterline Technologies: Limited Upside

2018-06-11 seekingalpha
Esterline Technologies is a strong, stable company with about $2 billion in annual revenue, with around $150 million in free cash flow per annum. (3-0)

Materion: Limited Upside For Now

2018-06-08 seekingalpha
Gross sales have surged well over +20% in the past TTM period, which has boded well for the share price, helped in part by the acquisition of Heraeus’ Target Materials. (2-0)

Self-Help And Stronger End-Markets A Powerful Combo For Materion

2018-06-07 seekingalpha
Materion has benefited from robust demand in key markets like consumer electronics and industrial products, while new product introductions have done their part as well. (2-0)

Materion's (MTRN) CEO Jugal Vijayvargiya on Q1 2018 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Greetings and welcome to the Materion Corporation’s First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host today, Mr. Steve Shamrock, you may begin. (10-0)

CUSIP: 576690101